Skip to main content
Explore URMC

Anton Pjetur Porsteinsson, M.D.

Contact Information

Phone Numbers

Appointment: (585) 273-5454

Administrative: (585) 760-6550

Office: (585) 760-6560

Fax: (585) 760-6572

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Research Labs

Faculty Appointments

Patient Care Setting



Dr. Porsteinsson is the Director of the University of Rochester Alzheimer's Disease Care, Research and Education Program (AD-CARE). In addition, he is the first William B. and Sheila Konar Professor of Psychiatry at the University of Rochester, School of Medicine and Dentistry. In 1987, he received his MD degree from the University of Iceland School of Medicine and came to the University of Rochester in 1989, where he completed his internship and residency. He is Board certified in Psychiatry, with added qualifications in Geriatric Psychiatry.
Dr. Porsteinsson has devoted his career to the care and study of individuals with memory disorders. He participates in the University of Rochester Memory Care Program, which serves a population with memory disorders. Internationally recognized in clinical research and considered one of the leading experts in Alzheimer's disease and dementia, his interests lie in biomarkers, imaging, and novel pharmacologic agents in the treatment of Alzheimer's disease and other dementias, both in terms of cognitive loss and behavioral disturbances. He is a leading investigator for many prominent national Alzheimer's prevention and treatment trials and has conducted major clinical trials with cognitive enhancers and course stabilizing agents in dementia, as well as psychotropics for behavioral changes associated with dementia. Dr. Porsteinsson is the author and collaborator of hundreds of research publications and serves as site principal investigator for research grants from the National Institutes of Health and other leading funders.



  • Geriatric Psychiatry
  • Psychiatry


| Univ Of Iceland

Post-doctoral Training & Residency

09/01/1990 - 06/30/1993
Residency in Psychiatry at University of Rochester Medical Center

09/01/1989 - 06/30/1990
Internship in Rotating at University of Rochester Medical Center

09/01/1987 - 06/30/1989
Internship in Rotating at University of Iceland

VIEW ALL expand_more


2012 - Present
Listed in Editions of America's Top Doctors

2010 - Present
Listed in editions of Distinguished Professionals

2010 - Present
Listed in editions of The Global Directory of Who's Who

Dr. John Baum Award, University of Rochester School of Medicine and Dentistry

2007 - Present
Listed in editions of Who's Who in America

Summer Research Institute Fellowship
Sponsor: NIMH/American Assoc. of Geriatric Psychiatry

The Helga Jonsdottir and Sigurlidi Kristjansson Memorial Award
Sponsor: NIMH/American Association of Geriatric Psychiatry

Carl Albert Jaenike Award
Sponsor: The Genesee Valley Psychiatric Assoc. & the Dept. of Psychiatry
Location: Rochester, NY

Residents' Recognition Award
Sponsor: University of Rochester School of Medicine and Dentistry
Location: Rochester, NY

Consultation-Liaison Award
Sponsor: University of Rochester School of Medicine and Dentistry
Location: Rochester, NY

Thorvaldur Thoroddsens Memorial Award
Sponsor: Reykjavik College
Location: Reykjavik, Iceland

P.O. Christensens Memorial Award
Sponsor: Reykjavik College
Location: Reykjavik, Iceland

VIEW ALL expand_more

Clinical Trials

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Study Evaluating the Safety and Efficacy of Simufilam 100 mg Tablets in Subjects With Mild-to-Moderate Alzheimer's Disease

Lead Researcher: Anton Pjetur Porsteinsson

A 52-week safety and efficacy study of simufilam (PTI-125) given twice daily to participants with mild-to-moderate Alzheimer's disease (AD) for 52 weeks. Approximately 750 participants will be randomized (1:1) to receive either placebo or 100 mg tablets of simufilam, twice daily, for 52 weeks. Clinic visits will occur 4 weeks after the baseline visit, and then every 12 weeks until the end of the study. The safety of simufilam, and its efficacy in enhancing cognition and slowing cognitive and functional decline will be evaluated.

View Study Details


Journal Articles

Lin F, Ren P, Lo Y, Chapman B, Jacobs A, Baran T, Porsteinsson AP, Foxe J. "Insula and Inferior Frontal Gyrus' Activations Protect Memory Performance Against Alzheimer's Pathology in Old Age. ." J Alzheimers Dis. 2017; 55(2): 669-678.

Lin F, Ren P, Mapstone M, Meyers S, Porsteinsson AP, Baran TM. "The Cingulate Cortex of Older Adults with Excellent Memory Capacity". Cortex. 2017; : 83-92.

Leonpacher A, Peters ME, Drye LT, Makino KM, Newell J, Devanand DP, Frangakis C, Mintzer JE, Munro CA, Pollock BG, Rosenberg PB, Schneider LS, Shade DM, Weintraub D, Yesavage J, Lyketsos CG, Porsteinsson AP: For the CitAD Research Group. "Effects of Citalopram on Neuropsychiatric Symptoms in Alzheimer's Dementia: Evidence from the CitAD Study". Am J Psychiatry. 2016; 173(5): 473-80.

Books & Chapters

Chapter Title: Nursing Homes and Long Term Care.
Book Title: Neurodegenerative Dementias
Author List: Porsteinsson, AP; Tariot, PN;
Edited By: Trojanowski, JQ; Clark C.
Published By: McGraw-Hill Companies 1999 in New York

Chapter Title: Measurement of Behavioral Disturbances in Chronic Care Populations.
Book Title: Measurement in Elderly Chronic Care Populations
Author List: Tariot, PN; Porsteinsson, AP; Teri L; Weiner MF;
Edited By: Teresi, JA; Holmes, D; Ory, M;
Published By: Springer Publishing Company, Incorporated 1997 in New York




Combining Research and Care in URMC Memory Care Program


Types of Research in URMC Memory Care Program


URMC Memory Care Program